Association of thrombocytopenia and infection in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention

• Published in: BMC cardiovascular disorders Vol. 21; no. 1; p. 404
• Main Authors: Wang, Litao, Su, Weijiang, Xue, Jinhua, Gong, Xiao, Dai, Yining, Chen, Jiyan, Xue, Ling, He, Pengcheng, Liu, Yuanhui, Tan, Ning
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.08.2021; BioMed Central; BMC
• Subjects: Acute coronary syndromes; Aged; Angioplasty; Antibiotics; Care and treatment; China - epidemiology; Chronic obstructive pulmonary disease; Complications and side effects; Coronaviruses; COVID-19; Creatinine; Cross Infection - diagnosis; Cross Infection - epidemiology; Cross Infection - mortality; Death; Demographic aspects; Diabetes; Diagnosis; Female; Heart attack; Heart attacks; Hemoglobin; Hospitalization; Hospitals; Humans; Infection; Infections; Infectious diseases; Male; Middle Aged; Mortality; Multivariate analysis; Myocardial infarction; Normal distribution; Patients; Percutaneous coronary intervention; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - mortality; Prevalence; Prognosis; Risk Assessment; Risk Factors; Sepsis; ST Elevation Myocardial Infarction - diagnosis; ST Elevation Myocardial Infarction - epidemiology; ST Elevation Myocardial Infarction - mortality; ST Elevation Myocardial Infarction - therapy; ST-elevation myocardial infarction; Thrombocytopenia; Thrombocytopenia - diagnosis; Thrombocytopenia - epidemiology; Thrombocytopenia - mortality; Time Factors; Treatment Outcome; Variables; China; Infection; Thrombocytopenia; ST-elevation myocardial infarction; Percutaneous coronary intervention
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-021-02210-3

The impact of thrombocytopenia on infection in patients with ST-elevation myocardial infarction (STEMI) remains poorly understood. To evaluate the association between thrombocytopenia and infection in patients with STEMI. Patients diagnosed with STEMI were identified from January 2010 to June 2016. The primary endpoint was in-hospital infection, and major adverse clinical events (MACE) and all-cause death were considered as secondary endpoints. A total of 1401 STEMI patients were enrolled and divided into two groups according to the presence (n = 186) or absence (n = 1215) of thrombocytopenia. The prevalence of in-hospital infection was significantly higher in the thrombocytopenic group (30.6% (57/186) vs. 16.2% (197/1215), p < 0.001). Prevalence of in-hospital MACE (30.1% (56/186) vs. 16.4% (199/1215), p < 0.001) and all-cause death (8.1% (15/186) vs. 3.8% (46/1215), p = 0.008) revealed an increasing trend. Multivariate analysis indicated that thrombocytopenia was independently associated with increased in-hospital infection (OR, 2.09; 95%CI 1.32-3.27; p = 0.001) and MACE (1.92; 1.27-2.87; p = 0.002), but not all-cause death (1.87; 0.88-3.78; p = 0.091). After a median follow-up of 2.85 years, thrombocytopenia was not associated with all-cause death at multivariable analysis (adjusted hazard ratio, 1.19; 95%CI 0.80-1.77; p = 0.383). Thrombocytopenia is significantly correlated with in-hospital infection and MACE, and might be used as a prognostic tool in patients with STEMI.